Does Quartz Health Solutions Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Matter?

Vyvanse (lisdexamfetamine dimesylate) is a Schedule II central nervous system stimulant approved by the FDA in 2007 for ADHD and in 2015 for moderate-to-severe binge-eating disorder (BED) in adults. The FDA prescribing information confirms these two indications. Because it is a branded, Schedule II controlled substance, insurers including Quartz Health Solutions apply stricter coverage rules than they do for generic stimulants.

Why Schedule II Status Affects Your Formulary Tier

Schedule II controlled substances cannot legally be dispensed with automatic refills or called in by phone in most states. Pharmacies must receive a new written or electronic prescription each month. Insurers often place these drugs on higher formulary tiers partly because of acquisition cost and partly because of utilization management concerns. The result is higher cost-sharing for the patient.

The Arrival of Generic Lisdexamfetamine

Generic lisdexamfetamine capsules entered the U.S. Market in 2023 after Takeda's exclusivity period ended. The FDA maintains a searchable list of approved generic equivalents at the Orange Book. Several Quartz plans now place generic lisdexamfetamine at a lower tier than the brand, which can meaningfully cut your copay. Always ask your pharmacist to run the generic before assuming you need the brand.

ADHD Prevalence and Treatment Context

The CDC estimates that approximately 6 million U.S. Children aged 3 to 17 have ever received an ADHD diagnosis, and adult ADHD prevalence sits near 4.4% of the general population. CDC data on ADHD underscores why coverage decisions for stimulants affect a large share of any insurer's member population. Quartz, headquartered in Madison, Wisconsin, serves Wisconsin and parts of neighboring states, so its formulary decisions affect tens of thousands of people managing ADHD.

How Quartz Health Solutions Organizes Its Formulary

Quartz uses a tiered formulary structure common to most commercial insurers. Each tier carries a different copay or coinsurance rate, and the tier assignment for a drug can differ between Quartz's HMO, PPO, and HSA-qualified high-deductible plans.

Typical Tier Structure

Most Quartz commercial plans follow a four-tier or five-tier model:

• Tier 1: Preferred generics (lowest cost-sharing, often $0, $10).
• Tier 2: Non-preferred generics and some low-cost brands.
• Tier 3: Preferred brand-name drugs, typically $40, $75 per fill.
• Tier 4: Non-preferred brands and some specialty drugs, often $80, $150+ per fill.
• Tier 5 (select plans): Specialty drugs, typically coinsurance-based (20 to 30% of drug cost).

Brand Vyvanse commonly lands at Tier 3 or Tier 4 on Quartz commercial plans. Generic lisdexamfetamine may sit at Tier 2 on plans updated after the 2023 generic launch. FDA guidance on drug pricing and formulary placement explains the regulatory basis for generic substitution.

Where to Find Your Specific Tier

Your plan's Summary of Benefits and Coverage (SBC) and the full drug formulary PDF are available on the Quartz member portal. The formulary is updated at least annually and sometimes mid-year. Search for "lisdexamfetamine" rather than "Vyvanse" in the formulary search tool, because the generic name will catch both brand and generic entries.

Prior Authorization: What Quartz Typically Requires

Prior authorization (PA) is a formal review process in which Quartz evaluates whether a prescribed drug meets its clinical coverage criteria before agreeing to pay. For Vyvanse and generic lisdexamfetamine, PA is required on most Quartz plans.

Standard Clinical Criteria

Based on publicly available Quartz clinical coverage guidelines and standard industry PA criteria for ADHD stimulants, the following documentation is typically needed:

1. A confirmed DSM-5 diagnosis of ADHD or moderate-to-severe binge-eating disorder from a licensed provider. DSM-5 diagnostic criteria for ADHD require inattention or hyperactivity-impulsivity symptoms present before age 12 and causing impairment in two or more settings.
2. Documentation of a prior adequate trial (usually 4 to 8 weeks at a therapeutic dose) of at least one lower-tier stimulant, such as amphetamine salts (Adderall generics) or methylphenidate (Ritalin, Concerta generics), unless a contraindication or intolerance is documented.
3. Prescriber attestation that the patient is being monitored for cardiovascular effects and substance-use risk.
4. For BED: documentation that the diagnosis meets DSM-5 severity criteria and that behavioral or dietary interventions were attempted.

How Long PA Takes

Federal law (the No Surprises Act and CMS regulations) requires most plans to issue PA decisions within 72 hours for urgent requests and within 7 calendar days for standard requests. CMS prior authorization final rule (CMS-0057-F) sets minimum timelines. Quartz must comply with these federal standards for its ACA-compliant plans.

What Happens If PA Is Denied

A PA denial is not the end of the road. Federal law requires insurers to provide a written explanation and to offer at least one internal appeal. The MHPAEA, enforced by the Department of Labor, prohibits plans from applying more restrictive PA criteria to mental health conditions like ADHD than they apply to comparable medical or surgical conditions. MHPAEA guidance from the NIH-linked literature and DOL enforcement data support using parity arguments in ADHD-related appeals.

Step-by-Step: Getting Vyvanse Covered Through Quartz

Step 1. Confirm Your Plan's Formulary Status

Log into the Quartz member portal and search "lisdexamfetamine." Note the tier and whether a PA icon appears next to the drug. If you are not yet a Quartz member, request the full formulary PDF from the plan's sales or customer-service line before enrollment.

Step 2. Have Your Prescriber Submit the PA Request

Your prescribing clinician's office submits a PA request to Quartz using the drug's NDC code and your diagnosis code (ICD-10 F90.0, F90.9 for ADHD subtypes; F50.81 for BED). The prescriber should include:

• Office notes documenting symptom onset and impairment.
• Records of prior stimulant trials with dates, doses, and reasons for discontinuation.
• Any standardized rating-scale results (e.g., the Adult ADHD Self-Report Scale, or ASRS, validated in Kessler et al., 2005, Psychological Medicine).

Step 3. Request a Peer-to-Peer Review if Denied

If Quartz issues a denial, your prescriber can request a peer-to-peer (P2P) conversation with Quartz's medical director or reviewing clinician. P2P conversations overturn an estimated 20 to 40% of initial PA denials in managed care settings, according to a 2020 analysis in JAMA Internal Medicine. Your prescriber should come prepared with specific clinical evidence, not just a repeat of the chart notes.

Step 4. File a Formal Internal Appeal

You (the patient) or your prescriber can submit a written internal appeal within the timeframe Quartz specifies in the denial letter, typically 180 days. Include:

• The denial letter.
• A letter of medical necessity from your prescriber.
• Published clinical guidelines supporting lisdexamfetamine use (see the American Academy of Pediatrics 2019 ADHD guidelines at Pediatrics journal or the American Academy of Child and Adolescent Psychiatry practice parameter).
• Any peer-reviewed literature comparing response rates across stimulant classes.

Step 5. Request an External Independent Review

If the internal appeal is denied, you have the right to an external review by an independent organization under the ACA. External reviewers overturn insurer decisions at meaningful rates. A KFF analysis of ACA external reviews found that enrollees who pursued external review won a reversal in roughly 40 to 60% of cases in recent years.

Cost Without Full Coverage: Real Numbers

If your PA is denied, you exhaust your appeals, or your plan simply does not cover lisdexamfetamine, you have several options.

Cash Price for Brand vs. Generic

• Brand Vyvanse 30 mg, 70 mg: approximately $380, $430 for a 30-count supply at major Wisconsin pharmacies as of early 2025.
• Generic lisdexamfetamine (various manufacturers): approximately $60, $120 for a 30-count supply, depending on dose and pharmacy.

The FDA's MedWatch and drug pricing transparency initiatives do not set retail prices, but the generic entry has driven substantial competition. GoodRx-type discount programs can reduce the generic further to $40, $80 at some pharmacies.

Takeda's Patient Assistance Program

Takeda Pharmaceuticals offers the Vyvanse Savings Card for commercially insured patients and a separate patient-assistance program (PAP) for uninsured or underinsured individuals. Takeda's patient support information is coordinated through the prescriber's office. The savings card has historically reduced brand-name cost to $30 per fill for eligible patients, though income limits and insurance status restrictions apply.

Switching to a Covered Stimulant

Mixed amphetamine salts (generic Adderall), dextroamphetamine, and methylphenidate formulations are almost universally placed at Tier 1 or Tier 2 on Quartz plans. A large 2018 systematic review in The Lancet Psychiatry (78 trials, N>14,000) ranked amphetamines as the most effective stimulant class for adults with ADHD by effect size, and methylphenidate as the most effective for children. Your prescriber may be able to achieve similar symptom control with a covered alternative, depending on your specific response history.

The Clinical Case for Lisdexamfetamine Specifically

Not every patient with ADHD responds the same way to every stimulant. Lisdexamfetamine has a distinctive pharmacokinetic profile: it is a prodrug converted to d-amphetamine in red blood cells, which produces a slower rise to peak plasma concentration and a longer duration of action (up to 14 hours) compared with immediate-release amphetamine salts.

Efficacy Data

The key Phase III trial for Vyvanse in adult ADHD (NCT00334880) found statistically significant improvement on the ADHD Rating Scale-IV at doses of 30 mg, 50 mg, and 70 mg versus placebo (P<0.001 for all active doses). Results were published in CNS Spectrums and indexed on PubMed. This controlled-release mechanism is the clinical rationale prescribers use to justify lisdexamfetamine over immediate-release alternatives when requesting a PA.

BED Indication Data

Two key trials (Study 1 and Study 2, both Phase III, N=383 and N=390 respectively) showed that lisdexamfetamine 50 mg and 70 mg significantly reduced binge-eating days per week versus placebo. Results appear in McElroy et al., 2015, JAMA Psychiatry. For the BED indication, insurance criteria may differ: some plans require that a structured behavioral intervention (such as cognitive behavioral therapy, CBT) be documented before approving a stimulant, because CBT alone carries strong evidence for BED per Wilfley et al. In Psychological Medicine.

Cardiovascular Monitoring Requirement

The FDA-approved label for lisdexamfetamine includes a boxed warning about the potential for abuse and dependence, and a strong recommendation to assess cardiovascular status before prescribing. The American Heart Association's 2008 scientific statement on ADHD medications and cardiovascular risk (Vetter et al.) recommends a cardiac history and physical examination before initiating stimulants in children and adults. Quartz PA criteria typically require prescriber attestation that this assessment occurred.

Mental Health Parity: A Legal Tool in Coverage Disputes

The Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008, extended by the ACA, requires that quantitative and non-quantitative treatment limitations (NQTLs) applied to mental health or substance-use disorder benefits be no more restrictive than those applied to medical and surgical benefits. ADHD is a mental health condition under MHPAEA.

If Quartz requires a two-stimulant step-therapy trial before approving lisdexamfetamine for ADHD, but does not require an equivalent "step therapy" (e.g., trial of two statins) before approving a preferred cholesterol drug, that asymmetry may constitute an MHPAEA violation. Federal MHPAEA enforcement guidance (EBSA Technical Release 2023-01) outlines how plans must document their NQTL analyses. Patients or their providers can file a complaint with the Department of Labor or their state insurance commissioner if parity violations are suspected. Wisconsin's Office of the Commissioner of Insurance (OCI) handles state-level complaints.

Wisconsin-Specific Considerations for Quartz Members

Quartz Health Solutions is a Wisconsin-based insurer subject to Wisconsin insurance regulations in addition to federal rules. Wisconsin statutes (Wis. Stat. § 632.895) require certain mental-health benefit mandates, which may interact with MHPAEA requirements favorably for ADHD coverage disputes.

State External Review Rights

Wisconsin requires independent external review for most coverage denials. The Wisconsin OCI's external review process provides a second layer of oversight beyond what federal law alone requires. Filing timelines and procedures are available through the OCI directly.

Medicaid and BadgerCare Coverage

If you are covered through Wisconsin Medicaid (BadgerCare Plus) administered by Quartz as a managed care organization (MCO), the formulary and PA criteria may differ substantially from commercial plans. Medicaid drug rebate program guidance from CMS means that certain drugs have mandatory coverage categories under Medicaid. Contact Quartz's BadgerCare member services line for the Medicaid-specific formulary.

When Quartz Will Not Cover Vyvanse: Documented Exclusions

Some Quartz plan designs explicitly exclude brand-name drugs when a generic equivalent exists. Since generic lisdexamfetamine launched in 2023, some plans invoke a "generic substitution required" rule that denies brand Vyvanse regardless of PA. In that scenario, you can request brand-medically-necessary (BMN) exception if your prescriber documents a clinical reason the generic is inadequate (for example, a documented allergy to a specific inactive ingredient in the generic formulation not present in the brand).

Cosmetic, experimental, or off-label uses that fall outside FDA-approved indications are also grounds for denial. Lisdexamfetamine is FDA-approved only for ADHD and BED. Use for weight management alone, cognitive enhancement in non-ADHD individuals, or other off-label purposes would not meet Quartz's coverage criteria and would not be supported by guideline-based appeals. The FDA's guidance on off-label drug use clarifies the regulatory position.

Documenting ADHD for Insurance Purposes: What Your Records Need

A prescriber's note that says only "patient reports attention problems, start Vyvanse" will not survive a PA review. Quartz, like most insurers, expects documentation consistent with published diagnostic standards.

Required Diagnostic Elements

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline (Pediatrics, 2019) and the American Academy of Child and Adolescent Psychiatry (AACAP) practice parameters specify:

• Symptom count: at least 6 of 9 inattentive or hyperactive-impulsive symptoms for children; 5 of 9 for adults 17 and older.
• Symptom duration: present for at least 6 months, inconsistent with developmental level.
• Age of onset: several symptoms present before age 12.
• Cross-setting impairment: symptoms cause problems in at least two settings (school/work and home are the standard pair).
• Differential diagnosis: ruling out mood disorder, anxiety, learning disabilities, or medical causes.

Standardized rating scales such as the Vanderbilt ADHD Diagnostic Rating Scale (pediatric) or the Adult ADHD Self-Report Scale (ASRS v1.1), validated in Kessler et al., Psychological Medicine, 2005, provide objective scoring data that strengthens both the initial PA submission and any subsequent appeal.

Alternatives to Vyvanse That Quartz Typically Covers

If prior authorization is denied and appeals are unsuccessful, several covered alternatives are worth discussing with your prescriber.

Tier 1 and Tier 2 Stimulant Options

• Mixed amphetamine salts (generic Adderall, generic Adderall XR): The most widely prescribed ADHD stimulants in the U.S. Immediate-release and extended-release formulations exist. A 2021 network meta-analysis in The Lancet Psychiatry (Cortese et al.) ranked amphetamines highest for adult ADHD by standardized mean difference.
• Methylphenidate (generic Ritalin, generic Concerta, generic Focalin): Multiple formulations across different release profiles. Concerta generics have had bioequivalence controversies; confirm with your pharmacist which generics Quartz's pharmacy benefit manager (PBM) accepts.
• Dextroamphetamine (generic Dexedrine): Shorter duration but useful for patients who tolerate amphetamine but not the mixed-salt formulation.

Non-Stimulant Options

• Atomoxetine (generic Strattera): A selective norepinephrine reuptake inhibitor. Not a Schedule II drug. Approved for ADHD in adults and children. Onset of therapeutic effect takes 4 to 8 weeks. FDA label for atomoxetine outlines dosing.
• Viloxazine (Qelbree): FDA-approved in 2021 for children 6 to 17 and extended to adults in 2023. Non-stimulant, non-controlled. Some Quartz plans cover it at Tier 3; PA may still apply.
• Guanfacine ER (generic Intuniv) and Clonidine ER (generic Kapvay): Alpha-2 agonists with modest ADHD efficacy, often used as adjuncts or in patients who cannot tolerate stimulants. NIH review of non-stimulant ADHD pharmacotherapy summarizes the evidence base.

Practical Checklist Before Calling Quartz

Use this list before you spend an hour on hold:

1. Pull the current formulary PDF from the Quartz member portal and locate lisdexamfetamine by generic name.
2. Note the tier and whether a PA requirement symbol appears.
3. Call the member-services number on your insurance card and ask specifically: "Is prior authorization required for lisdexamfetamine for ADHD, and what are the step-therapy requirements?"
4. Ask whether the plan applies a "generic mandatory substitution" rule for lisdexamfetamine.
5. Confirm which ICD-10 diagnosis codes are accepted for PA (F90.0 through F90.9 for ADHD; F50.81 for BED).
6. Ask about the appeals timeline if PA is denied, and request the written PA criteria document.
7. Share all of this information with your prescriber before they submit the PA, so the clinical documentation matches exactly what Quartz expects.

The national average PA approval rate for ADHD stimulants is not publicly reported by Quartz, but a 2022 AMA prior authorization survey found that 94% of physicians reported PA delays and 82% reported that PA caused patients to abandon treatment at least sometimes. Preparation on both the patient's and prescriber's side shortens the timeline substantially.